Creso Pharma (ASX:CPH) - Creso Pharma - The Market Herald

" Creso Pharma (ASX:CPH) launches ecommerce channels, enters Polish markets

Creso Pharma (CPH) has launched new e-commerce channels and expanded into Poland with a maiden purchase order secured.
Emyria (ASX:EMD) contracts consultant for psychedelics and MDMA research

" Emyria (ASX:EMD) contracts consultant for psychedelics and MDMA research

Emyria (EMD) has appointed a consultant to support its psychedelic-assisted therapy programs.
Healthia (ASX:HLA) - CEO, Wesley Coote - The Market Herald

" Healthia (ASX:HLA) up on Rothwell Physiotherapy buy

Healthia (HLA) shares have enjoyed a 10 per cent rise after reporting a $1.62 million acquisition of Queensland’s Rothwell Physiotherapy.
AnteoTech (ASX:ADO) - CEO, Derek Thomson - The Market Herald

" AnteoTech (ASX:ADO) ticks off another distribution deal for EuGeni

AnteoTech (ADO) has signed a distribution agreement with Ramma Dental for its EuGeni Reader platform and SARS-CoV-2 Antigen Rapid Diagnostic Test (RDT).
BARD1 Life Sciences (ASX:BD1) - CEO, Leearne Hinch - The Market Herald

" BARD1 (ASX:BD1) appoints world-leading medical researcher as CSO

BARD1 Life Sciences (BD1) has appointed medical researcher Greg Rice to the role of chief scientific officer (CSO) to fast-track development its diagnostic
EMVision (ASX:EMV) - Chairman, John Keep - The Market Herald

" EMVision Medical Devices (ASX:EMV) signs $8m project agreement with ASA

EMVision Medical Devices (EMV) has signed an $8 million project agreement with The Australian Stroke Alliance (ASA).
Amplia Therapeutics - CEO and MD, John Lambert - The Market Herald

" Amplia Therapeutics (ASX:ATX) completes design for Phase 2 trial in first-line pancreatic cancer patients

Amplia Therapeutics (ATX) has completed the design for a Phase 2 clinical trial in first-line pancreatic cancer patients.
Patrys (ASX:PAB) - CEO and MD, James Campbell - The Market Herald

" Patrys (ASX:PAB) shows deoxymab potential in antibody drug conjugates

Patrys (PAB) has wrapped up a preclinical study highlighting the potential of its deoxymab antibodies as targeting agents in antibody drug conjugates (ADCs).
Orthocell (ASX:OCC) - Chief Scientific Officer, Minghao Zheng - The Market Herald

" Orthocell (ASX:OCC) announces positive data on CelGro collagen rope for ACL repair

Orthocell (OCC) has completed its pre-clinical study for anterior cruciate ligament (ACL) reconstruction.
Argenica Therapeutics (ASX:AGN)- CEO, Dr Liz Dallimore (left) and COO,Dr Samantha South (right) - The Market Herald

" Argenica (ASX:AGN) achieves manufacturing milestones

Argenica Therapeutics (AGN) has confirmed two of its manufacturing partners have successfully scaled-up the manufacturing of ARG-007.